Alex Sigal is a South Africa–based virologist at the Africa Health Research Institute (AHRI) in Durban, South Africa, Max Plank Institute for Infection Biology in Berlin, and University of KwaZulu-Natal in Durban. His work concentrates on evolution and persistence of the SARS-CoV-2 virus. His laboratory was the first to isolate the live B.1.351 (Beta) variant of SARS-CoV-2 first detected in South Africa. Sigal’s laboratory was also the first to report results on the ability of the Omicron variant to escape antibody neutralization in individuals who had two doses of the Pfizer BNT162b2 vaccine as well as from previous infections, with results also suggesting that vaccination combined with a booster or previous infection can offer protection from symptomatic infection with Omicron.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| |
rdfs:comment
| - Alex Sigal is a South Africa–based virologist at the Africa Health Research Institute (AHRI) in Durban, South Africa, Max Plank Institute for Infection Biology in Berlin, and University of KwaZulu-Natal in Durban. His work concentrates on evolution and persistence of the SARS-CoV-2 virus. His laboratory was the first to isolate the live B.1.351 (Beta) variant of SARS-CoV-2 first detected in South Africa. Sigal’s laboratory was also the first to report results on the ability of the Omicron variant to escape antibody neutralization in individuals who had two doses of the Pfizer BNT162b2 vaccine as well as from previous infections, with results also suggesting that vaccination combined with a booster or previous infection can offer protection from symptomatic infection with Omicron. (en)
|
foaf:name
| |
foaf:homepage
| |
name
| |
foaf:depiction
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
workplaces
| - University of KwaZulu-Natal (en)
- Africa Health Research Institute (en)
- Max Plank Institute for Infection Biology (en)
|
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
alma mater
| - BSc, University of Toronto, (en)
- PhD, Weizmann Institute of Science (en)
|
awards
| - EMBO Fellow (en)
- Human Frontiers Career Development Award (en)
- Human Frontiers Long-Term fellowship (en)
|
birth date
| |
caption
| |
citizenship
| |
fields
| |
image size
| |
known for
| - Isolation of SARS-CoV-2 Beta variant; establishing ability of Beta and Omicron variants to escape antibody neutralization from previous infections and vaccines. (en)
|
website
| |
has abstract
| - Alex Sigal is a South Africa–based virologist at the Africa Health Research Institute (AHRI) in Durban, South Africa, Max Plank Institute for Infection Biology in Berlin, and University of KwaZulu-Natal in Durban. His work concentrates on evolution and persistence of the SARS-CoV-2 virus. His laboratory was the first to isolate the live B.1.351 (Beta) variant of SARS-CoV-2 first detected in South Africa. Sigal’s laboratory was also the first to report results on the ability of the Omicron variant to escape antibody neutralization in individuals who had two doses of the Pfizer BNT162b2 vaccine as well as from previous infections, with results also suggesting that vaccination combined with a booster or previous infection can offer protection from symptomatic infection with Omicron. (en)
|
academic advisors
| |
doctoral advisor
| |
academic advisor
| |
doctoral advisor
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is Wikipage disambiguates
of | |
is foaf:primaryTopic
of | |